Viridian Therapeutics Statistics Share Statistics Viridian Therapeutics has 81.66M
shares outstanding. The number of shares has increased by 3.09%
in one year.
Shares Outstanding 81.66M Shares Change (YoY) 3.09% Shares Change (QoQ) 0.09% Owned by Institutions (%) 99.99% Shares Floating 66.94M Failed to Deliver (FTD) Shares 194 FTD / Avg. Volume 0.03%
Short Selling Information The latest short interest is 11M, so 13.47% of the outstanding
shares have been sold short.
Short Interest 11M Short % of Shares Out 13.47% Short % of Float 14.07% Short Ratio (days to cover) 12.33
Valuation Ratios The PE ratio is -4.82 and the forward
PE ratio is -5.25.
Viridian Therapeutics's PEG ratio is
0.19.
PE Ratio -4.82 Forward PE -5.25 PS Ratio 4309.19 Forward PS 32.2 PB Ratio 1.94 P/FCF Ratio -5.59 PEG Ratio 0.19
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Viridian Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 15.43,
with a Debt / Equity ratio of 0.03.
Current Ratio 15.43 Quick Ratio 15.43 Debt / Equity 0.03 Debt / EBITDA -0.08 Debt / FCF -0.09 Interest Coverage -98.17
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $2.11K Profits Per Employee $-1.89M Employee Count 143 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax n/a Effective Tax Rate 0%
Stock Price Statistics The stock price has increased by -9.49% in the
last 52 weeks. The beta is 0.54, so Viridian Therapeutics's
price volatility has been higher than the market average.
Beta 0.54 52-Week Price Change -9.49% 50-Day Moving Average 18.74 200-Day Moving Average 16.49 Relative Strength Index (RSI) 66.73 Average Volume (20 Days) 766,733
Income Statement In the last 12 months, Viridian Therapeutics had revenue of 302K
and earned -269.95M
in profits. Earnings per share was -3.98.
Revenue 302K Gross Profit 302K Operating Income -299.04M Net Income -269.95M EBITDA -265.66M EBIT -266.9M Earnings Per Share (EPS) -3.98
Full Income Statement Balance Sheet The company has 99.59M in cash and 21.09M in
debt, giving a net cash position of 78.5M.
Cash & Cash Equivalents 99.59M Total Debt 21.09M Net Cash 78.5M Retained Earnings -995.86M Total Assets 582.32M Working Capital 526.16M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -232.32M
and capital expenditures -511K, giving a free cash flow of -232.83M.
Operating Cash Flow -232.32M Capital Expenditures -511K Free Cash Flow -232.83M FCF Per Share -3.43
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of -99018.21% and -89387.09%.
Gross Margin 100% Operating Margin -99018.21% Pretax Margin -89387.09% Profit Margin -89387.09% EBITDA Margin -87967.88% EBIT Margin -99018.21% FCF Margin -77096.03%
Dividends & Yields VRDN does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for VRDN is $34,
which is 57% higher than the current price. The consensus rating is "Buy".
Price Target $34 Price Target Difference 57% Analyst Consensus Buy Analyst Count 8
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 13, 2020. It was a
backward
split with a ratio of 1:15.
Last Split Date Nov 13, 2020 Split Type backward Split Ratio 1:15
Scores Altman Z-Score 10.6 Piotroski F-Score 3
